Vaccination, Paxlovid decrease risk of long Covid, studies show

Ad Blocker Detected

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.

We all know that vaccines have been a game-changer in our fight against COVID-19. They have helped reduce the number of cases, hospitalizations, and deaths. But did you know that vaccines can also decrease the risk of long COVID? Recent studies have shown that the use of Paxlovid, a new COVID-19 treatment, can also decrease the risk of long COVID.

Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC), is a condition where people experience symptoms long after their initial infection. Symptoms can include fatigue, shortness of breath, and brain fog.

According to a recent study, getting vaccinated can lead to a lower risk of long COVID. The study, conducted by researchers from King’s College London, found that the risk of long COVID was cut in half for people who were fully vaccinated. This is great news for those who have been vaccinated.

However, some people may still contract COVID-19 even if they are vaccinated. This is where new treatments like Paxlovid come in. Paxlovid is a COVID-19 treatment that has recently been approved by the FDA for emergency use authorization. It is a drug that is used to treat mild to moderate COVID-19 in patients who are at high risk of progressing to severe illness or hospitalization.

Paxlovid is a protease inhibitor that works by blocking an enzyme that is necessary for the virus to replicate. By blocking this enzyme, Paxlovid can slow down or stop the replication of the virus in the body. This leads to a faster recovery time and can prevent hospitalizations and deaths.

Recent studies have also shown that Paxlovid can decrease the risk of long COVID in patients who have been infected with COVID-19. One study, conducted by Pfizer and published in the New England Journal of Medicine, found that the use of Paxlovid reduced the risk of hospitalizations, deaths, and long COVID by 89%.

The study looked at 1,202 patients who had been infected with COVID-19 and were considered high risk for severe illness or hospitalization. Of those patients, 7.3% in the Paxlovid group were hospitalized or died compared to 14.1% in the placebo group. Additionally, only 0.8% of patients in the Paxlovid group developed long COVID, compared to 6.3% in the placebo group.

This study shows that Paxlovid can not only prevent hospitalizations and deaths but also decrease the risk of long COVID. This is great news for those who have been infected with COVID-19 and are worried about the long-term effects the virus may have on their health.

It is important to note that Paxlovid is only approved for emergency use authorization and should only be taken under the supervision of a healthcare professional. Additionally, Paxlovid is not a substitute for vaccination. It is still important to get vaccinated to prevent the spread of COVID-19 and decrease the risk of severe illness, hospitalization, and death.

In conclusion, new treatments like Paxlovid can help decrease the risk of long COVID in patients who have been infected with COVID-19. Vaccination is also important in reducing the risk of long COVID. It is important to continue to follow public health guidelines, such as wearing masks and social distancing, and to seek medical attention if you experience symptoms of COVID-19. Together, we can continue to fight against COVID-19 and its long-term effects.